Fate Therapeutics Inc (FATE): Forward Price-to-Revenue Multiple
Fate Therapeutics, Inc. (FATE) is attracting leading biologists to develop immunotherapies by supporting its scientific staff with generous RSUs and budgets. Clinical expenses are covered by existing cash reserves, a fact reflected in the forward P/S dynamics, where the latest value is recorded as 33.10. Business revenues are based on grants and payments from strategic pharmaceutical partners for the development of oncology treatments.
Analytical breakdowns for Fate Therapeutics, Inc. (FATE)
- current price and projected stock value:
- stock exchange capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Fate Therapeutics, Inc.|FATE - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Fate Therapeutics|FATE - Aggregate Debt Obligations|Debts to Book Capitalization Fate Pharma|FATE - Long-Term Debt|Company Short-Term Debt Fate Therapeutics|Quick Ratio fatetherapeutics.com
- financial results and valuation multiples details:
FATE - Net Profit|Expected Profit Fate Therapeutics, Inc.|FATE - Market Cap to Net Income|Forward P/E Multiple Fate Therapeutics Inc|FATE - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Fate Therapeutics|FATE - Operating profit EBITDA|Net earnings per share for the last 12 months Fate Therapeutics|FATE - Earnings per share for the last four quarters|Quarterly EPS earnings growth fatetherapeutics.com|FATE - Expected net earnings per share growth this year|Earnings growth forecast for next year Fate Therapeutics, Inc.
- revenue and sales details:
Summary company analysis:fatetherapeutics.com FATE
For the biotechnology sector, where Fate Therapeutics, Inc. (FATE) is developing its iPSC platform, this indicator serves as a tool for assessing market expectations regarding future revenue. The forward P/S ratio is calculated as the ratio of current market capitalization to expected annual sales, allowing investors to use this chart to compare asset value against the potential of new alliances and clinical trial successes.
Competitor analysis
Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology Therapeutics (CGON) - Price-to-Projected Revenue Ratio|Projected Price to Revenue UroGen Pharma URGN|Price-to-Projected Revenue Ratio Bicara Bio|Market Cap to Future Revenue Ratio Personalis Genomics PSNL|Forward P/S Multiple ERAS|Price to Expected Revenue Ratio DCTH|Y-mAbs Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Aura Biosciences Inc (AURA)|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc.)|SLS: Forward P/S Multiple|ACTU: Price to Expected Revenue Ratio|CTOR (Citius Oncology Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tuhurabio.com HURA|Forward P/S Multiple TARA|Market Cap to Expected Sales Ratio Aadi Bioscience|Price-to-Projected Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Projected Revenue|XBIT: Forward Price-to-Revenue Multiple|Forward Price to Sales CVM (cel-sci.com)|OSTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Forward P/S Multiple|Market Cap to Projected Revenue ANL (Adlai Nortye)|Price-to-Projected Revenue Ratio Veru Pharma (VERU)|Forward P/S Multiple Tempest Tx (TPST)|Price-to-Projected Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Projected Revenue Ratio|Mural Oncology - Forward P/S Multiple|KAPA - Forward P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CytoMed|Price-to-Projected Revenue Ratio curis.com|Forward Price-to-Revenue Multiple Apollomics, Inc. (APLM)|Forward P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Genprex GNPX|Market Cap to Expected Sales Ratio Calidi Bio (CLDI)|sunshinebiopharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Projected Revenue Ratio|Purple Biotech Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio AON|Forward P/S Multiple BeiGene Ltd.|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple
